Department Pharmaceutical Sciences at the Faculty of Medicine and Life Sciences, University of Latvia, provide a full set of experimental testing from two-dimensional (2D) and three-dimensional (3D) cell culture models, including patient-derived organoids, pancreatic, kidney and liver organ-on-chip microfluidics systems, and induced pluripotent stem cell (iPSC) technologies, to in vivo zebrafish model, followed by tissue analysis, evaluation of genetic and epigenetic biomarkers by utilizing machine learning models to predict the progression of disease and therapy efficacy, analyzing cell interaction in tumor microenvironment and assessing compound toxicity.
Representatives
full professor
Department of Pharmaceutical Sciences, University of Latvia
Lead researcher
Department of Pharmaceutical Sciences, University of Latvia
Rare disease patient-derived iPSC models for personalized therapy development
Partner seeks Consortium/Coordinator
DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
Author
full professor at Department of Pharmaceutical Sciences, University of Latvia
Our zebrafish avatar NAM offers 3R-compliant, real-time efficacy and toxicity profiling of patient-derived grafts in transgenic fish.
Partner seeks Consortium/Coordinator
DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
Author
Lead researcher at Department of Pharmaceutical Sciences, University of Latvia